Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10259791 High-purity quinoline derivative and method for manufacturing same

Patent 10259791 was granted and assigned to Eisai on April, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Yusuke Ayata0

Hirofumi Kuroda0

Taichi Abe0

Taiju Nakamura0

Atsushi Akao0

Yusuke Miyashita0

Date of Patent

April 16, 2019

Patent Application Number

15503108

Date Filed

August 26, 2015

Patent Citations Received

US Patent 12083112 Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer

0

US Patent 11547705 Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

US Patent 10822307 High-purity quinoline derivative and method for manufacturing same

US Patent 11598776 Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

US Patent 11369623 Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

0

US Patent 11925639 Tumor-treating pharmaceutical composition

0

Patent Primary Examiner

D Margaret M Seaman

Patent abstract

Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10259791 High-purity quinoline derivative and method for manufacturing same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool